BB Biotech AG
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Investment Focus
ISIN-No. CH0038389992
BB Biotech aims to achieve an average annual double-digit return over the long term, thus outperforming the broad market indices by a significant margin. BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs.
Indexed performance (as at: 18.07.2024)
Share price: EUR 44.65 (18.07.2024)
NAV: EUR 47.65 (18.07.2024)
Rolling performance (18.07.2024)
Share Price | NAV | Benchmark | |
18.07.2023 - 18.07.2024 | -1.04% | 16.02% | 21.18% |
18.07.2022 - 18.07.2023 | -15.22% | -7.41% | -2.11% |
16.07.2021 - 18.07.2022 | -20.69% | -16.63% | -9.75% |
17.07.2020 - 16.07.2021 | 23.48% | 6.43% | 8.04% |
Annualized performance (18.07.2024)
Share Price | NAV | Benchmark | |
1 year | -1.04% | 16.02% | 21.78% |
3 years | -12.66% | -3.60% | 2.30% |
5 years | -0.71% | 4.13% | 9.25% |
10 years | 11.11% | 9.97% | 9.59% |
Since Inception p.a. | 11.81% | 12.01% | 11.30% |
Cumulative performance (18.07.2024)
Share Price | NAV | Benchmark | |
1M | 9.44% | 12.51% | 6.51% |
YTD | 2.44% | 9.15% | 12.88% |
1 year | -1.04% | 16.02% | 21.78% |
3 years | -33.46% | -10.44% | 7.06% |
5 years | -3.49% | 22.47% | 55.70% |
10 years | 186.98% | 158.91% | 150.03% |
Since Inception | 1'841.35% | 1'933.36% | 1'618.45% |
Annual performance
Share Price | NAV | Benchmark | |
2023 | -15.21% | -1.29% | 1.26% |
2022 | -19.00% | -6.72% | -4.46% |
2021 | 13.34% | -7.79% | 7.39% |
2020 | 18.06% | 24.77% | 16.12% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management AG |
Custodian | Bank Julius Bär AG |
Fund Administrator | Bellevue Asset Management AG |
Auditor | Deloitte AG |
Launch date | 09.11.1993 |
Year end closing | 31. Dec |
Management Fee | 1.10% |
ISIN number | CH0038389992 |
Valor number | 3838999 |
Bloomberg | BBZA GY Equity |
WKN | A0NFN3 |
Legal Information
Legal form | Incorporate company |
SFDR category | Article 8 |
Key data (30.04.2024, base currency CHF)
Beta | 1.28 |
Volatility | 31.90 |
Tracking error | 14.15 |
Active share | 83.27 |
Correlation | 0.92 |
Sharpe ratio | -0.13 |
Information ratio | -0.16 |
Jensen's alpha | -1.71 |
No. of positions | 33 |
Portfolio as at 31.03.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
In June we saw important positive updates from the portfolio companies including Alnylam, Argenx, Agios and Intra-Cellular. Alnylam highlighted the month with their highly anticipated topline results from the HELIOS-B phase-III-trial in ATTR.
Please find below selected highlights from a few of BB Biotech´s portfolio companies:
Alnylam (+63.7%, in USD) announced on June 24 positive topline results from its HELIOS-B Phase-III-study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary composite endpoint of all-cause mortality and recurrent CV hospitalization in both the monotherapy and overall populations. The study also demonstrated statistically significant improvements across all secondary endpoints in both populations. Alnylam will present more comprehensive data at the European Society of Cardiology Congress in late Aug/early Sept 2024.
Agios Pharmaceuticals (+18.7%, in USD) announced on June 3 that the global Phase-III-study ENERGIZE-T of mitapivat in adults with transfusion-dependent (TD) alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response. Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.
Argenx (+15.9%, in USD) announced on June 21st that the FDA has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). It is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP.
Intra-Cellular Therapies (+1.9%, in USD) announced on June 18 that in Phase-III-study 502, lumateperone 42mg achieved statistically significant results in major depressive disorder (MDD). Study 502 replicated the robust treatment effect seen in their first Phase-III-study MDD (501), further strengthening lumateperone’s consistent, best-in-class clinical and safety profile in the adjunctive MDD setting. These data should support strong commercial uptake pending approval in 2025.
Documents
Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). Show moreShow less